Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 and Olaparib in Advanced Cancer With MTAP Loss
NCT07382544Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MRTX1719 in solid tumor (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Feb 2026; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07382544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382544.